TX-FLUENCE
2.9.2021 14:02:06 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, and HortiPolaris, a Beijing, China-based greenhouse producing 20 varieties of tomatoes and eight types of lettuce, announced the implementation of Fluence LED lighting solutions into HortiPolaris’s cultivation and research facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005266/en/
HortiPolaris is a science and technology leader in the region, standing on the cutting edge of farming and education in booming Beijing where the population and demand for fresh, quality produce continues to grow. Its state-of-the-art greenhouse—inspired by the founder’s work in the Netherlands—represents the future of controlled environment agriculture, housing 2,000 square meters of lettuce and 22,850 square meters of tomatoes. HortiPolaris originally equipped its farm with HPS lighting, but found energy costs were too high for a market that valued quality over yield, prompting the company to switch to LED lighting systems that provide crop consistency, energy efficiency and seasonal cultivation flexibility for growers.
“We can use LEDs not only in the winter period, but also in the spring, autumn and even summer to increase yield and stabilize quality,” said Dan Xu, founder and general manager of HortiPolaris. “We are carrying out trials together with Fluence to figure out the best combination of light intensity and light spectrum in order to increase the neutral level to maximize margin and to differentiate ourselves in the market.”
HortiPolaris distributes a variety of popular tomato and lettuce cultivars to local and regional markets and leverages Fluence’s broad-spectrum VYPR LED lighting solutions in its greenhouse and Fluence’s RAZR LED solutions in HortiPolaris’s vertical propagation racks.
“Transitioning from HPS lighting to Fluence LED solutions affords growers a way to improve the quality of their produce such as color and consistency—critical factors shoppers in the growing Beijing region are prioritizing,” said David Cohen, CEO of Fluence. “We are proud to partner with HortiPolaris, an innovator and evolved horticulture leader in the rapidly expanding Chinese market, that recognizes the advantages of LED technology developmentally for crops’ growing cycles and also operationally in facility design.”
Applying Fluence’s LED lighting solutions provides growers better control over plants’ external variables such as temperature and humidity, eliminating once-crucial concerns about overheating as a result of growing under HPS lighting.
“There are several advantages to Fluence lighting solutions,” said Yuchong Chen, technical assistant at HortiPolaris. “Not only can they provide maximum light intensity, but they also allow us to control intensity for different growing stages. Additionally, the uniform light the RAZR fixtures provide is quite important for grafting. That’s why we use Fluence LED lighting solutions in all seasons to increase yield and stabilize the quality of our grow.”
Fluence’s partnership with HortiPolaris bolsters the farm’s ability to harvest quality produce and supply the market year-round. The companies’ ongoing trials to discover optimum lighting strategies for unique cultivation environments are charting the course for the future of innovative food production that will ultimately help the world grow smarter.
To learn more about Fluence, its customers and the company’s ongoing research, visit www.fluence.science/case-studies .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom